Loading
Latest filing published 15 Aug 2023 for GT Biopharma, Inc., €52k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Michael Martin Breen across 2 companies, led by GT Biopharma, Inc. and Prairie Operating Co. Between 16 February 2021 and 11 August 2023, the trades on record add up to 8 filings.
The open-market record is one-sided, with 2 purchases worth €113k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants. Since January 2023: 2 purchases and no sales on the market.
The newest entry dates from 15 August 2023: a share grant of €52k, in GT Biopharma, Inc. The clock since the last published purchase (5 May 2023) now reads 1,268 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations